Sigachi Industries Presents Q4 FY26 Investor Presentation, Outlines FY27 Guidance
Sigachi Industries released its Q4 FY26 investor presentation. The Dahej-2 capacity expansion is progressing, aiming for 30,000 MTPA by Q4 FY27. For FY27, the company targets Rs. 6,500-6,750 million in revenue with an 18-20% EBITDA margin.
The investor presentation provides forward-looking guidance and updates on expansion plans, which are material for investors. However, it does not contain immediate, drastic changes to business operations or financial structure.
The announcement is an investor presentation providing an update on performance and future guidance. While it outlines growth plans and targets, the reported financial results for FY26 show a significant net loss, balancing the positive outlook.
Sigachi Industries Limited has released its Investor Presentation for the fourth quarter of the fiscal year 2025-26 (Q4 FY26), providing an update on its operational and financial performance, along with guidance for FY27.
The presentation highlights the company's progress on its Dahej-2 capacity expansion, which is on schedule with civil works underway, aiming to elevate total MCC capacity to 30,000 MTPA. The new API R&D Centre in Hyderabad is now fully operational. The company emphasizes its strong global presence, serving over 500 customers across 65+ countries from its four state-of-the-art manufacturing facilities.
Financially, for Q4 FY26, Sigachi reported Revenue from Operational Income of Rs. 1,219 million, EBITDA of Rs. 154 million with a margin of 12.63%, and PAT of Rs. 76 million. For the full fiscal year FY26, Revenue was Rs. 4,778 million, with EBITDA at Rs. 537 million and a PAT of Rs. (828) million. The company also detailed its ESG performance, focusing on waste management, energy consumption, employee wellbeing, CSR initiatives, and corporate governance.
Looking ahead to FY27, Sigachi has provided guidance including a revenue target of Rs. 6,500-6,750 million, an EBITDA margin of 18%-20%, and a capacity utilization of over 65% post the Dahej-2 ramp-up by Q4 FY27. The company anticipates stable global pharma excipient demand and higher margin contributions from its API portfolio.
What to do with a filing like this
Sigachi Industries Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sigachi Industries Limited. Read the original for the full detail.